{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:35:19Z","timestamp":1793262919803,"version":"4.5.0"},"reference-count":97,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T00:00:00Z","timestamp":1618531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>\n                    Graves\u2019 disease (GD) is an organ-specific autoimmune disorder of the thyroid, which is characterized by circulating TSH-receptor (TSH-R) stimulating antibodies (TSAb), leading to hyperthyroidism. Graves\u2019 ophthalmopathy (GO) is one of GD extra-thyroidal manifestations associated with the presence of TSAb, and insulin-like growth factor-1 receptor (IGF-1R) autoantibodies, that interact with orbital fibroblasts. Cytokines are elevated in autoimmune (i.e., IL-18, IL-6) and non-autoimmune hyperthyroidism (i.e., TNF-\u03b1, IL-8, IL-6), and this could be associated with the chronic effects of thyroid hormone increase. A prevalent Th1-immune response (not related to the hyperthyroidism\n                    <jats:italic>per se<\/jats:italic>\n                    , but to the autoimmune process) is reported in the immune-pathogenesis of GD and GO; Th1-chemokines (CXCL9, CXCL10, CXCL11) and the (C-X-C)R3 receptor are crucial in this process. In patients with active GO, corticosteroids, or intravenous immunoglobulins, decrease inflammation and orbital congestion, and are considered first-line therapies. The more deepened understanding of GO pathophysiology has led to different immune-modulant treatments. Cytokines, TSH-R, and IGF-1R (on the surface of B and T lymphocytes, and fibroblasts), and chemokines implicated in the autoimmune process, are possible targets of novel therapies. Drugs that target cytokines (etanercept, tocilizumab, infliximab, adalimumab) have been tested in GO, with encouraging results. The chimeric monoclonal antibody directed against CD20, RTX, reduces B lymphocytes, cytokines and the released autoantibodies. A multicenter, randomized, placebo-controlled, double-masked trial has investigated the human monoclonal blocking antibody directed against IGF-1R, teprotumumab, reporting its effectiveness in GO. In conclusion, large, controlled and randomized studies are needed to evaluate new possible targeted therapies for GO.\n                  <\/jats:p>","DOI":"10.3389\/fendo.2021.654473","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T15:02:20Z","timestamp":1618585340000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":44,"title":["Cytokines as Targets of Novel Therapies for Graves\u2019 Ophthalmopathy"],"prefix":"10.3389","volume":"12","author":[{"given":"Poupak","family":"Fallahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia Martina","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ragusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Rosaria","family":"Paparo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Patrizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Camastra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Miccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Cavallini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Benvenga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.10.016","article-title":"Autoimmune thyroid disorders","volume":"14","author":"Antonelli","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 disease","volume":"375","author":"Smith","year":"2016","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2020.101387","article-title":"Graves\u2019 disease: Epidemiology, genetic and environmental risk factors and viruses","volume":"34","author":"Antonelli","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-019-0305-4","article-title":"New insights into the pathogenesis and nonsurgical management of Graves orbitopathy","volume":"16","author":"Taylor","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g5128","article-title":"Diagnosis and management of thyrotoxicosis","volume":"349","author":"Vaidya","year":"2014","journal-title":"BMJ"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2020.101388","article-title":"Graves\u2019 disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy","volume":"34","author":"Antonelli","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.1998.tb04951.x","article-title":"The Th1\/Th2 paradigm and allergic disorders","volume":"53","author":"Romagnani","year":"1998","journal-title":"Allergy"},{"key":"B8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1210\/er.2013-1055","article-title":"Breaking tolerance to thyroid antigens: changing concepts in thyroid autoimmunity","volume":"35","author":"McLachlan","year":"2014","journal-title":"Endocr Rev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ando.2018.09.002","article-title":"Graves\u2019 disease: introduction, epidemiology, endogenous and environmental pathogenic factors","volume":"79","author":"W\u00e9meau","year":"2018","journal-title":"Ann Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcte.2019.100196","article-title":"Chemokines in hyperthyroidism","volume":"16","author":"Ferrari","year":"2019","journal-title":"J Clin Transl Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000001052","article-title":"Thyrotropin receptor antibodies-an overview","volume":"34","author":"Kotwal","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz292","article-title":"Prospective Trial of Functional Thyrotropin Receptor Antibodies in Graves Disease","volume":"105","author":"Kahaly","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.10.001","article-title":"The association of other autoimmune diseases in patients with Graves\u2019 disease (with or without ophthalmopathy): review of the literature and report of a large series","volume":"18","author":"Ferrari","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B14","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13023-017-0625-1","article-title":"Graves\u2019 orbitopathy as a rare disease in Europe: a European Group on Graves\u2019 Orbitopathy (EUGOGO) position statement","volume":"12","author":"Perros","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-020-0184-y","article-title":"Graves\u2019 disease","volume":"6","author":"Davies","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B16","unstructured":"DaviesTF\n            BurchHB\n          Clinical features and diagnosis of Graves\u2019 orbitopathy (ophthalmopathy)2019"},{"key":"B17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000443828","article-title":"The 2016 European Thyroid Association\/European Group on Graves\u2019 Orbitopathy Guidelines for the Management of Graves\u2019 Orbitopathy","volume":"5","author":"Bartalena","year":"2016","journal-title":"Eur Thyroid J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.01.001","article-title":"Smoke and autoimmunity: the fire behind the disease","volume":"15","author":"Perricone","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1210\/jc.2006-1824","article-title":"Smoking and thyroid- associated ophthalmopathy: a novel explanation of the biological link","volume":"92","author":"Cawood","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/7453260","article-title":"Immunological Aspects of Graves\u2019 Ophthalmopathy","volume":"2019","author":"\u0141acheta","year":"2019","journal-title":"Biomed Res Int"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13693","article-title":"Inhibiting thyrotropin\/insulin-like growth factor 1 receptor crosstalk to treat Graves\u2019 ophthalmopathy: studies in orbital fibro blasts in vitro","volume":"174","author":"Place","year":"2017","journal-title":"Br J Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1530\/acta.0.1260013","article-title":"High-dose intravenous immunoglobulin treatment in Graves\u2019 ophthalmopathy","volume":"126","author":"Antonelli","year":"1992","journal-title":"Acta Endocrinol (Copenh)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1210\/jc.2013-3919","article-title":"A prospective, randomized trial of intravenous glucocorticoids therapy with different protocols for patients with graves\u2019 ophthalmopathy","volume":"99","author":"Zhu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-1962","article-title":"J. Clinical review: intravenous glucocorticoids for Graves\u2019 orbitopathy: efficacy and morbidity","volume":"96","author":"Zang","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-017-0608-z","article-title":"Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves\u2019 orbitopathy","volume":"40","author":"Bartalena","year":"2017","journal-title":"J Endocrinol Invest"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-2758","article-title":"Efficacy and safety of orbital radiotherapy for Graves\u2019 orbitopathy","volume":"97","author":"Tanda","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1089\/thy.2013.0445","article-title":"Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy","volume":"24","author":"Curr\u00f2","year":"2014","journal-title":"Thyroid"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2016.1157468","article-title":"Novel Therapies for Thyroid Autoimmune Diseases","volume":"9","author":"Fallahi","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2019.101366","article-title":"Novel therapies for thyroid autoimmune diseases: An update","volume":"34","author":"Ferrari","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1045-9","article-title":"Current and Emerging Treatment Strategies for Graves\u2019 Orbitopathy","volume":"79","author":"Genere","year":"2019","journal-title":"Drugs"},{"key":"B31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1530\/JME-10-0127","article-title":"Crystal structure of the TSH receptor (TSHR) bound to a blocking-type TSHR autoantibody","volume":"46","author":"Sanders","year":"2011","journal-title":"J Mol Endocrinol"},{"key":"B32","unstructured":""},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1149","article-title":"A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy","volume":"98","author":"Turcu","year":"2013","journal-title":"J Clin Endocrinol Metabol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2016.00167","article-title":"Building the case for insulin-like growth factor receptor-I involvement in thyroid-associated ophthalmopathy","volume":"7","author":"Smith","year":"2016","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00066","article-title":"Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy","volume":"40","author":"Smith","year":"2019","journal-title":"Endocr Rev"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000493","article-title":"Immunotherapies for thyroid eye disease","volume":"26","author":"Kahaly","year":"2019","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1530\/JME-17-0276","article-title":"IGF1 receptor and thyroid-associated ophthalmopathy","volume":"61","author":"Mohyi","year":"2018","journal-title":"J Mol Endocrinol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1580","article-title":"Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes","volume":"99","author":"Chen","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for Thyroid-Associated Ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the Treatment of Active Thyroid Eye Disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2020.101383","article-title":"Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy","volume":"34","author":"Smith","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B42","unstructured":"Horizon therapeutics plc announces the FDA has granted priority review of the teprotumumab biologics license application (BLA) for the treatment of active thyroid eye disease (TED)2019"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.07.008","article-title":"Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature","volume":"14","author":"Giuggioli","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2111","article-title":"Efficacy and safety of rituximab for the treatment of graves\u2019 orbitopathy: a meta-analysis of randomized controlled trials","volume":"38","author":"Shen","year":"2018","journal-title":"Pharmacotherapy"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2018.1453078","article-title":"Low-dose rituximab for active moderate to severe graves\u2019 orbitopathy resistant to conventional treatment","volume":"27","author":"Du Pasquier-Fediaevsky","year":"2019","journal-title":"Ocul Immunol Inflamm"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13970","article-title":"Early low-dose rituximab for active thyroid eye disease: an effective and well-tolerated treatment","volume":"91","author":"Insull","year":"2019","journal-title":"Clin Endocrinol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1177\/1120672119845224","article-title":"The effects of Rituximab on Graves\u2019orbitopathy: a retrospective study of 14 patients","volume":"30","author":"Eid","year":"2019","journal-title":"Eur J Ophthalmol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2362.1993.tb00712.x","article-title":"Detection and localization of cytokine immunoreactivity in retro-ocular connective tissue in Graves\u2019 ophthalmopathy","volume":"23","author":"Heufelder","year":"1993","journal-title":"Eur J Clin Invest"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2002.01792.x","article-title":"Unlocking the immunological mechanisms of orbital inflammation in thyroid eye disease","volume":"127","author":"Ludgate","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2010.02.002","article-title":"Cytokines (interferon-\u03b3- and tumor necrosis factor-\u03b1)-induced nuclear factor-\u03baB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone","volume":"60","author":"Antonelli","year":"2011","journal-title":"Metabolism"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1689","article-title":"Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves\u2019 ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists","volume":"91","author":"Antonelli","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2450","article-title":"Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves\u2019 disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists","volume":"94","author":"Antonelli","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-01493","article-title":"Potential roles of CD34+ fibrocytes masquerading as orbital fibroblasts in thyroid-associated ophthalmopathy","volume":"104","author":"Smith","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-20199","article-title":"IL-17A Promotes RANTES Expression, But Not IL-16, in Orbital Fibroblasts Via CD40-CD40L Combination in Thyroid-Associated Ophthalmopathy","volume":"57","author":"Fang","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.05.004","article-title":"Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves\u2019 disease and ophthalmopathy","volume":"18","author":"Ferrari","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2008.03219.x","article-title":"Role of macrophage infiltration in the orbital fat of patients with Graves\u2019 ophthalmopathy","volume":"69","author":"Chen","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.08.025","article-title":"Extra-ocular muscle cells from patients with Graves\u2019 ophthalmopathy secrete \u03b1 (CXCL10) and \u03b2 (CCL2) chemokines under the influence of cytokines that are modulated by PPAR\u03b3","volume":"13","author":"Antonelli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021897","article-title":"An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4","volume":"197","author":"Lasagni","year":"2003","journal-title":"J Exp Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation \u2013 a target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.10.010","article-title":"Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases","volume":"13","author":"Antonelli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2905","article-title":"Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis","volume":"96","author":"Antonelli","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2010.01.009","article-title":"Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists","volume":"50","author":"Antonelli","year":"2010","journal-title":"Cytokine"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.09.009","article-title":"The association of other autoimmune diseases in patients with autoimmune thyroiditis: review of the literature and report of a large series of patients","volume":"15","author":"Fallahi","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B66","article-title":"Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis","volume":"35","author":"Antonelli","year":"2008","journal-title":"J Rheumatol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1080\/08916930802170401","article-title":"High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis","volume":"41","author":"Antonelli","year":"2008","journal-title":"Autoimmunity"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.7417\/CT.2013.1594","article-title":"HCV-related autoimmune disorders in HCV chronic infection","volume":"164","author":"Ferrari","year":"2013","journal-title":"Clin Ter"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2012.04.042","article-title":"Variable modulation by cytokines and thiazolidinediones of the prototype Th1 chemokine CXCL10 in anaplastic thyroid cancer","volume":"59","author":"Antonelli","year":"2012","journal-title":"Cytokine"},{"key":"B70","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.3390\/ijms20184413","article-title":"Immune and Inflammatory Cells in Thyroid Cancer Microenvironment","volume":"20","author":"Ferrari","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.2.5436","article-title":"Serum cytokines in thyrotoxicosis","volume":"84","author":"Siddiqi","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"B72","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1530\/eje.0.1430197","article-title":"Serum concentrations of proinflammatory cytokines in Graves\u2019 disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking","volume":"143","author":"Salvi","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02137","article-title":"Increased serum CXCL10 in Graves\u2019 disease or autoimmune thyroiditis is not associated with hyper- or hypothyroidism per se, but is specifically sustained by the autoimmune, inflammatory process","volume":"154","author":"Antonelli","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz289","article-title":"Th1 Chemokines in Autoimmune Endocrine Disorders","volume":"105","author":"Fallahi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-005-5457-9","article-title":"Thyroid hormone-induced oxidative stress","volume":"63","author":"Venditti","year":"2006","journal-title":"Cell Mol Life Sci"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237015","article-title":"Protein tyrosine phosphatase 1B as a therapeutic target for Graves\u2019 orbitopathy in an in vitro model","volume":"15","author":"Byeon","year":"2020","journal-title":"PloS One"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1210\/en.2005-1018","article-title":"T helper type 1 and type 2 cytokines exert divergent influence on the induction of prostaglandin E2 and hyaluronan synthesis by interleukin-1\u03b2 in orbital fibroblasts: implications for the pathogenesis of thyroidassociated ophthalmopathy","volume":"147","author":"Han","year":"2006","journal-title":"Endocrinology"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.2.1310","article-title":"IL-1 beta induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotypic attribute relevant to thyroid- associated ophthalmopathy","volume":"175","author":"Chen","year":"2005","journal-title":"J Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.5603\/EP.2014.0021","article-title":"The role of the immune system and cytokines involved in the pathogenesis of autoimmune thyroid disease (AITD)","volume":"65","author":"Miko\u015b","year":"2014","journal-title":"Endokrynol Pol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-2328","article-title":"Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyper induces IL-6, IL-8, and MCP-1","volume":"50","author":"Hwang","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B81","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1074\/jbc.M110.164772","article-title":"Prostaglandin E2 activates and utilizes mTORC2 as a central signaling locus for the regulation of mast cell chemotaxis and mediator release","volume":"286","author":"Kuehn","year":"2011","journal-title":"J Biol Chem"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.09-3789","article-title":"The expression of intercellular adhesion molecule-1 induced by CD40-CD40L ligand signaling in orbital fibroblasts in patients with Graves\u2019 ophthalmopathy, Invest","volume":"51","author":"Zhao","year":"2010","journal-title":"Opthalmol Vis Sci"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900434","article-title":"Slit2 may underlie divergent induction by thyrotropin of IL-23 and IL-12 in human fibrocytes","volume":"204","author":"Fernando","year":"2020","journal-title":"J Immunol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa684","article-title":"Slit2 regulates hyaluronan & cytokine synthesis in fibrocytes: Potential relevance to thyroid associated ophthalmopathy","volume":"106","author":"Fernando","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa959","article-title":"Slit2 regulation of hyaluronan & cytokine synthesis in fibrocytes in thyroid associated ophthalmopathy","volume":"136","author":"Antonelli","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.0806","article-title":"Association of T and B cells infiltrating orbital tissues with clinical features of graves orbitopathy","volume":"136","author":"Rotondo Dottore","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1080\/17469899.2016.1202113","article-title":"Thyroid eye disease \u2014 an update","volume":"11","author":"Draman","year":"2016","journal-title":"Expert Rev Ophthalmol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.5114\/ceji.2019.92803","article-title":"Etanercept in the treatment of Graves\u2019 ophthalmopathy with primary hypothyroidism and rheumatoid arthritis","volume":"44","author":"Boskovic","year":"2019","journal-title":"Cent Eur J Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/sj.eye.6701768","article-title":"The effect of etanercept on Graves\u2019 ophthalmopathy: a pilot study","volume":"19","author":"Paridaens","year":"2005","journal-title":"Eye (Lond)"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-017-0694-0","article-title":"Advances in the management of thyroid eye diseases: An overview","volume":"38","author":"Kumari","year":"2018","journal-title":"Int Ophthalmol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000402","article-title":"Update on Graves disease: advances in treatment of mild, moderate and severe thyroid eye disease","volume":"28","author":"Strianese","year":"2017","journal-title":"Curr Opin Ophthalmol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000001131","article-title":"Efficacy and Safety of Immunosuppressive Agents for Thyroid Eye Disease","volume":"34","author":"Strianese","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B93","article-title":"Monoclonal anti-TNF-alpha antibody (infliximab) in the treatment of patient with thyroid associated ophthalmopathy","volume":"109","author":"Komorowski","year":"2007","journal-title":"Klin Oczna"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000000211","article-title":"Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease","volume":"30","author":"Ayabe","year":"2014","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1097\/IOP.0000000000000037","article-title":"Treatment of active corticosteroid-resistant graves\u2019 orbitopathy","volume":"30","author":"P\u00e9rez-Moreiras","year":"2014","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.oftal.2018.04.011","article-title":"Response to tocilizumab treatment in Graves\u2019 ophthalmopathy by measuring rectus muscle thickness and chemosis using optical coherence tomography","volume":"93","author":"de-Pablo-G\u00f3mez-de-Lia\u00f1o","year":"2018","journal-title":"Arch Soc Esp Oftalmol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2018.1545914","article-title":"Tocilizumab for the Management of Corticosteroid-Resistant Mild to Severe Graves\u2019 Ophthalmopathy, a Report of Three Cases","volume":"28","author":"Maldiney","year":"2020","journal-title":"Ocul Immunol Inflamm"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.654473\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T15:02:36Z","timestamp":1618585356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.654473\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,16]]},"references-count":97,"alternative-id":["10.3389\/fendo.2021.654473"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.654473","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,16]]},"article-number":"654473"}}